… Short acting beta2-agonists (SABAs) such as salbutamol and terbutaline are commonly …
with short-acting bronchodilators (including beta2-agonists or anticholinergics) when it is …

… An inhaled corticosteroid combined with a long acting beta2-agonists is more effective than
… and mortality in patients with moderate-to-severe COPD, although there is an increased risk …

… of beta2 agonists not associated with steroids is strongly counter-indicated due to the added
risk of appearance of severe episodes of acute … In our country, short-acting beta2 agonists …

… Short-acting beta2-agonists (SABA) were the most frequent respiratory medications prescribed
in the 12 months before the index date among COPD patients aged ≥ 40 years in CPRD …

… Approximately 72% of individuals filled some reliever medication, most commonly short-acting
beta2-agonists (SABAs) as metered dose inhaler and SABA/SAMA nebulized solutions. …

… Asthmatic crisis and anaphylaxis require a rapid and early approach, with beta2-agonists
and adrenaline being the initial treatments of choice. We must consider their …

… Pharmacological prevention of exacerbations has been demonstrated in asthma using
monoclonal anti-IgE with long-acting inhaled beta2 agonists in addition to inhaled corticosteroid …

… Inhaled beta2-agonists can induce cardiac side effects in patients with HF, such as
ischaemia, tachycardia, arrhythmias, hypokalaemia, QT prolongation, disturbed autonomic …

… 5% of adults develop acute bronchitis, and its economic … in the treatment of patients with
acute bronchitis in Korea. The … a Bronchitis Severity Score (BSS) ≥5 due to acute bronchitis …

… Short-acting beta2 agonists (SABAs) promote mucus clearance by increasing airway luminal
diameter and ciliary beat frequency. The regular use of SABA in stable COPD is associated …